Centene (CNC) is back in focus after reporting Q1 2026 results that topped expectations and after securing multi-year Medicaid and Medicare related contracts in Nevada, Iowa, and Mississippi, prompting fresh attention on the stock’s setup.

The Q1 beat and fresh state contract wins come on top of strong recent share price momentum, with a 30 day share price return of 11.18% and a 90 day gain of 37.62%, even as the 5 year total shareholder return is down 16.90%.

If Centene’s move has you rethinking your healthcare exposure, it could be a good moment to scan for other managed care and digital health plays through our 39 healthcare AI stocks

With Centene trading near its analyst price target, yet screening as materially undervalued on at least one intrinsic value model, the key question for you is simple: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 8% Overvalued

Centene’s most followed valuation narrative pegs fair value at $54.94, slightly below the last close of $59.55. This frames the current debate around upside from here.

Centene's Medicaid business is expected to see margin recovery as rate adjustments align better with member acuity, which could improve Medicaid-related revenue and net margins. Overall strength and competitiveness in winning Medicaid contracts, such as the fully integrated D-SNP in Illinois and Medicaid expansion into rural Nevada, may drive future revenue growth and market share.

The narrative leans heavily on measured revenue gains, gradual margin repair and a reset earnings base. The real story sits in how those pieces compound over time and what payoff the model assigns to them. This helps explain why the valuation still leans cautious despite contract momentum.

Result: Fair Value of $54.94 (OVERVALUED)

However, there are still pressure points that could flip this story, including policy shifts around Medicaid rates and volatile medical costs such as flu spikes and specialty drugs.

Another View: DCF Says Deeply Undervalued

The analyst narrative indicates that Centene is around 8% overvalued at $59.55 compared with a fair value estimate of $54.94. Our DCF model, in contrast, points in the other direction, with an estimated future cash flow value of $199.72 per share, which is about 70% above the current price. Which signal do you trust more?

Next Steps

With sentiment clearly split, this is the moment to look at the numbers yourself and decide where you stand before the market moves on. To understand why some investors are optimistic, review the 3 key rewards

Looking for more investment ideas?

If Centene has sharpened your interest, do not stop here. Use the screener to spot other stocks that match your risk, income, and growth preferences.

• Zero in on potential mispricings by scanning markets for companies that look attractively valued using the 47 high quality undervalued stocks.
• Identify income ideas by reviewing stocks that combine higher yields with balance sheet support through the 10 dividend fortresses.
• Stay proactive by tracking companies with robust finances using the solid balance sheet and fundamentals stocks screener (47 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.